This study pioneered the cost-effectiveness analysis of TLE-CHM as a first-line therapy for HER2-negative advanced G/GEJ adenocarcinoma, providing a valuable reference for both China and the international community. This evidence concerns the gene CHM and gastroesophageal junction adenocarcinoma.